T1	Drug 24 35	brentuximab
T2	Procedure 69 90	allogeneic transplant
T3	Condition 128 150	primary cutaneous ALCL
T4	Condition 191 196	sALCL
*	OR T3 T4
T5	Condition 228 245	meningeal disease
T6	Condition 219 227;238 245	cerebral disease
T7	Condition 277 319	progressive multifocal leukoencephalopathy
T8	Condition 321 324	PML
R1	Subsumes Arg1:T7 Arg2:T8	
*	OR T5 T6
T9	Scope 219 245	cerebral/meningeal disease
R2	Subsumes Arg1:T9 Arg2:T7	
T10	Pregnancy_considerations 327 390	Female patients who are lactating and breastfeeding or pregnant
T11	Measurement 398 426	human immunodeficiency virus
T12	Measurement 428 431	HIV
R3	Subsumes Arg1:T11 Arg2:T12	
T13	Value 433 441	positive
R4	Has_value Arg1:T11 Arg2:T13	
T14	Measurement 449 476	hepatitis B surface antigen
T15	Value 477 485	positive
T16	Condition 516 537	hepatitis C infection
T17	Qualifier 509 515	active
R5	Has_qualifier Arg1:T16 Arg2:T17	
R6	Has_value Arg1:T14 Arg2:T15	
*	OR T14 T16
